PARP inhibitor resistance: the underlying mechanisms and clinical implications
Abstract Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi targeting poly (ADP-ribose) polymerase (PARP) have been approved for ovarian cancer and breast cancer indications...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12943-020-01227-0 |